May 13, 2020 / 12:45PM GMT
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Bluebird Bio Regulator Update Call. (Operator Instructions)
I would now like to hand the conference over to your speaker, Ingrid Goldberg. Please go ahead.
Ingrid Goldberg - bluebird bio, Inc. - VP of IR
Thank you. Good morning, everyone, and thank you for joining today's call. The format for today's call will be brief opening remarks from Nick. And then for the Q&A portion, we'll be joined by Dave and Chip as well as our Chief Business Officer and Head of Oncology, Joanne Smith-Farrell; and Chief Technology and Manufacturing Officer, Derek Adams.
Before we begin, I would like to remind everyone that we will make statements about the company's future plans and prospects that constitute forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in today's SEC filings. These forward-looking statements represent our estimates as of today and
bluebird bio Inc and Bristol-Myers Squibb Co to Provide Regulatory Update on Idecabtagene Vicleucel - Conference Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot